BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35341178)

  • 1. A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1.
    Zhao H; Dong X; Huang T; Li X
    Comput Intell Neurosci; 2022; 2022():9979200. PubMed ID: 35341178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.
    Xu J; Liu F; Li Y; Shen L
    Cell Mol Neurobiol; 2022 Apr; 42(3):709-722. PubMed ID: 32894375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin a upregulation in glioma: A potential therapeutic target associated with immune infiltration.
    Zhang M; Huang J; Wang Y; Nie Q; Zhang X; Yang Y; Mao G
    J Med Biochem; 2022 Oct; 41(4):459-465. PubMed ID: 36381072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma.
    Ma W; Mei P
    World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Expression and Clinical Significance of Aldo-Keto Reductase 1 Member B1 in Gastric Carcinoma.
    Li X; Yang J; Gu X; Xu J; Li H; Qian J; Chen L
    DNA Cell Biol; 2020 Jul; 39(7):1322-1327. PubMed ID: 32412859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer.
    Hojnik M; Šuster NK; Smrkolj Š; Sisinger D; Grazio SF; Verdenik I; Rižner TL
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatics Analysis Reveals the Vital Role of AKR1B1 in Immune Infiltration and Clinical Outcomes of Gastric Cancer.
    Zhao Z; Hao Z; Zhang Z; Zhan X
    DNA Cell Biol; 2023 Jul; 42(7):372-389. PubMed ID: 37285280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
    Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
    Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
    Yang G; Tang S; Zhang J; Qin L
    World Neurosurg; 2021 Apr; 148():e436-e449. PubMed ID: 33444836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas.
    Hojnik M; Frković Grazio S; Verdenik I; Rižner TL
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential.
    Khayami R; Hashemi SR; Kerachian MA
    J Cell Mol Med; 2020 Aug; 24(16):8890-8902. PubMed ID: 32633024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
    Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
    Front Genet; 2022; 13():1053263. PubMed ID: 36712869
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
    Lv L; Zhang Y; Zhao Y; Wei Q; Zhao Y; Yi Q
    Front Cell Neurosci; 2021; 15():704344. PubMed ID: 34335194
    [No Abstract]   [Full Text] [Related]  

  • 20. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
    Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
    Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.